5.54 0.86 (18.38%) | 03-27 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 7.26 | 1-year : | 8.48 |
Resists | First : | 6.21 | Second : | 7.26 |
Pivot price | 1.81 | |||
Supports | First : | 2.62 | Second : | 0.4 |
MAs | MA(5) : | 4.32 | MA(20) : | 1.52 |
MA(100) : | 0.77 | MA(250) : | 0.67 | |
MACD | MACD : | 1 | Signal : | 0.4 |
%K %D | K(14,3) : | 81.7 | D(3) : | 75.7 |
RSI | RSI(14): 82.1 | |||
52-week | High : | 6.21 | Low : | 0.33 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MBRX ] has closed below upper band by 5.8%. Bollinger Bands are 1591.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 5.69 - 5.72 | 5.72 - 5.75 |
Low: | 4.69 - 4.72 | 4.72 - 4.74 |
Close: | 5.49 - 5.54 | 5.54 - 5.59 |
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Thu, 28 Mar 2024
Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com - Defense World
Thu, 28 Mar 2024
Research Analysts Offer Predictions for Moleculin Biotech, Inc.'s FY2028 Earnings (NASDAQ:MBRX) - Defense World
Wed, 27 Mar 2024
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity – Company Announcement - FT ... - Financial Times
Wed, 27 Mar 2024
Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML - Seeking Alpha
Wed, 27 Mar 2024
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML - PR Newswire
Tue, 26 Mar 2024
Where Will Moleculin Biotech Inc (MBRX) Stock Go Next After It Is Down 40.59% in a Week? - InvestorsObserver
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 2 (M) |
Shares Float | 2 (M) |
Held by Insiders | 4.6 (%) |
Held by Institutions | 15.5 (%) |
Shares Short | 9 (K) |
Shares Short P.Month | 15 (K) |
EPS | -13.36 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 11.69 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -38.8 % |
Return on Equity (ttm) | -76.1 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -13.23 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -24 (M) |
Levered Free Cash Flow | -17 (M) |
PE Ratio | -0.42 |
PEG Ratio | 0 |
Price to Book value | 0.47 |
Price to Sales | 0 |
Price to Cash Flow | -0.52 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |